ESMO 2025

Oncology

ESMO25: Harnessing the innate and the adaptive immune respon...

As ESMO 2025 came to a close last month, pharmaphorum had the pleasure of catching up with Dr Sandeep Reddy, Chief Medical Officer at ImmunityBio.

Oncology

Interview at ESMO 2025 with Tadaaki Taniguchi

ESMO25: On next-generation bispecifics, with Tadaaki Taniguc...

At ESMO 2025 in Berlin, pharmaphorum spoke with Tadaaki Taniguchi, Chief Research & Development Officer at Astellas.

R&D

ESMO25: On partnerships between pharma and diagnostic develo...

Jane Li, Senior Director of Pharma CDx and CRO Partnership, Clinical Next Generation Sequencing Business, at Thermo Fisher Scientific discusses CDx.

Oncology

oncological practices today, with ESMO branding

5 clinical advances and related implications from ESMO 2025

5 particularly insightful takeaways from this year’s ESMO Congress that merit deeper reflection on where cancer care can go.

Oncology

Interview at ESMO 2025 with Inge Marie Svane

ESMO25: Immuno-therapies and translational research in oncol...

Dr Inge Marie Svane – Professor in Clinical cancer immune therapy and director of the translational research centre, CCIT, on IO Biotech's ESMO25 data

Oncology

ESMO25: The changing landscape of rare oncology, with Jan Ki...

ESMO sees many presentations on cancers of the lung, breast, and bladder - for example - but this year there was meaningful data in rare cancers, too.

ESMO25: Harnessing the innate and the adaptive immune respon...

ESMO25: On next-generation bispecifics, with Tadaaki Taniguc...

ESMO25: On partnerships between pharma and diagnostic develo...

5 clinical advances and related implications from ESMO 2025

ESMO25: Immuno-therapies and translational research in oncol...

ESMO25: The changing landscape of rare oncology, with Jan Ki...

Tenpoint eyes presbyopia drug launch after FDA nod

How to meet your physicians where they are online

ESMO 2025

Editor's Picks